Iontronic devices for controlled drug release with electronic precision
Marle Vleugels a, Donghak Byun a, Iwona Bernacka Wojcik a, Nikolaus Poremba b, Christian Bayer c, Sebastian Hecko b, Martin Wilkovitsch b, Theresia Arbring Sjöström a, Linda Waldherr c, Rainer Schindl c, Daniel Simon a, Hannes Mikula b, Johannes Bintinger a
a Laboratory of Organic Electronics, Dep. of Science and Technology, Linköping University, Norrköping (Sweden)
b TU Wien, Institute of Chemical Technologies and Analytics, Vienna, Austria
c Gottfried Schatz Research Center – Division of Medical Physics and Biophysics Medical University of Graz, Graz, 8010 Austria
Proceedings of Bioelectronic Interfaces: Materials, Devices and Applications (CyBioEl)
Limassol, Cyprus, 2024 October 22nd - 25th
Organizers: Eleni Stavrinidou and Achilleas Savva
Oral, Marle Vleugels, presentation 007
Publication date: 28th June 2024

Low delivery efficiency and toxicity of many chemotherapeutics limit their effectiveness in cancer treatment. Local chemotherapy is an approach to increase the effectiveness of cancer treatment. To enable not only spatial, but also temporal control of drug delivery, we utilize iontronic pumps (IPs). Drug delivery with IPs is achieved by electrophoretic transport of ions through ion-exchange membranes (IEM).1 IEMs consist of crosslinked networks of charged polymers that block transport of oppositely charged compounds. Important requirements for IEMs are ion-selectivity and passive leakage prevention. In case of ion-selective and low leakage IPs, electronic current corresponds to the ionic delivery current, thus providing a drug delivery platform with high dosage control. However, IP drug delivery is limited to low Mw and charged compounds, making it unsuitable for delivery of large or uncharged drugs.2 To expand the drug library with large and uncharged drugs, we envision the delivery of a small trigger for the release of potent chemotherapeutics via a bioorthogonal click-to-release mechanism. Ligation of the potent chemotherapeutics onto a hydrogel, located at the tumor site, ensures local release and high concentration of the drug and the bioorthogonal approach reduces side effects. Our goal is to control drug concentration profiles at the tumor site, which opens op avenues for spatiotemporally controlled administration of highly potent chemotherapeutics, without the need for systemic administration of (pro)drugs or drug conjugates.

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101099963

© FUNDACIO DE LA COMUNITAT VALENCIANA SCITO
We use our own and third party cookies for analysing and measuring usage of our website to improve our services. If you continue browsing, we consider accepting its use. You can check our Cookies Policy in which you will also find how to configure your web browser for the use of cookies. More info